Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Ceftazidime-avibactam for the treatment of infections caused by carbapenem-resistant Gram-negative pathogens in Chinese patients: A phase IV, multi-center, open‑label study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
10.3389/fcimb.2022.823684 · 2022 · External reference
Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review
2021 · External reference
Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy
10.1016/j.micres.2022.127249 · 2023 · External reference
Global and regional burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria in 2019: A systematic analysis from the MICROBE database
10.1016/j.ijid.2024.107769 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
WHO Bacterial Priority Pathogens List, 2024
2024 · External reference
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme
10.1093/jac/dkad280 · 2023 · External reference
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
10.1093/jac/dky204 · 2018 · External reference
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
10.1007/s40121-021-00507-6 · 2021 · External reference
Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis
10.1007/s40121-024-00999-y · 2024 · External reference
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
10.1016/s1473-3099(17)30747-8 · 2018 · External reference
Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA-specified end points
10.1093/ofid/ofz149 · 2019 · External reference
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
10.1093/cid/ciw133 · 2016 · External reference
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
10.1093/cid/ciw378 · 2016 · External reference
10.1016/s1473-3099(16)30004-4
10.1016/s1473-3099(16)30004-4 · 2016 · External reference
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
10.1016/j.ijantimicag.2017.01.010 · 2017 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli
10.1016/j.jmii.2023.01.017 · 2023 · External reference
Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms
10.1016/j.jmii.2022.02.001 · 2022 · External reference
Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China
10.3389/fcimb.2020.00314 · 2020 · External reference
Interval estimation for a binomial proportion
10.1214/ss/1009213286 · 2001 · External reference
One-sided confidence intervals in discrete distributions
10.1016/j.jspi.2004.01.005 · 2005 · External reference
Comparative analysis of two rates
10.1002/sim.4780040211 · 1985 · External reference
The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study
10.1007/s40121-023-00762-9 · 2023 · External reference
Ceftazidime-avibactam: effectiveness and safety in the clinical practice. A third hospital level experience
2022 · External reference
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
10.1093/ofid/ofz522 · 2019 · External reference
Analysis of the clinical application of ceftazidime-avibactam in China
10.1016/j.jiph.2022.02.003 · 2022 · External reference
